PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling ...

With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require ...

Investigators concluded that reference or biosimilar pegfilgrastim could be safely administered to patients with lymphoma on the same day they receive chemotherapy, which could reduce scheduling ...

A Cigna Healthcare study found administering pegfilgrastim, an injection used to prevent infection in cancer patients, in a home setting increased patient outcomes compared to administration in a ...

Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The dosage can ...

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) ...

Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma Whole-Genome Profiling of Pediatric Diffuse ...

Neulasta (pegfilgrastim) is a prescription drug used to prevent infection from certain cancer therapy and to treat radiation sickness. Neulasta’s cost may depend on factors such as your dosage and the ...

Tool-like receptor expression in osteosarcoma and neuroblastoma. Background: Progressive intensification of chemo-radiotherapy regimens has led to improved outcome of children with solid tumors.

REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), a commercial-stage biopharmaceutical company focused on the research, development and ...